Synthetic AAV/CRISPR vectors for blocking HIV‐1 expression in persistently infected astrocytes
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Astrocytes, the most abundant cells in the mammalian brain, perform key functions and are involved in several neurodegenerative diseases. The human immunodeficiency virus (HIV) can persist in astrocytes, contributing to the HIV burden and neurological dysfunctions in infected individuals. While a comprehensive approach to HIV cure must include the targeting of HIV‐1 in astrocytes, dedicated tools for this purpose are still lacking. Here we report a novel Adeno‐associated virus‐based vector (AAV9P1) with a synthetic surface peptide for transduction of astrocytes. Analysis of AAV9P1 transduction efficiencies with single brain cell populations, including primary human brain cells, as well as human brain organoids demonstrated that AAV9P1 targeted terminally differentiated human astrocytes much more efficiently than neurons. We then investigated whether AAV9P1 can be used to deliver HIV‐inhibitory genes to astrocytes. To this end we generated AAV9P1 vectors containing genes for HIV‐1 proviral editing by CRISPR/Cas9. Latently HIV‐1 infected astrocytes transduced with these vectors showed significantly diminished reactivation of proviruses, compared with untransduced cultures. Sequence analysis identified mutations/deletions in key HIV‐1 transcriptional control regions. We conclude that AAV9P1 is a promising tool for gene delivery to astrocytes and may facilitate inactivation/destruction of persisting HIV‐1 proviruses in astrocyte reservoirs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 3×
“These in vitro organoids consist of hiPSC-derived neurons and astrocytes and reflect the complexity of human brains more precisely compared with single cell-type cultures (Lancaster et al., 2013).”
BackgroundMethodInfluentialAstrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · cited 4×
“Mature astrocytes are characterized by a low self-renewal rate and long lifespans (Sofroniew & Vinters, 2010).”
BackgroundInfluentialDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Azevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337 · cited 2×
“7 3 10(10) cells in humans; [Azevedo et al., 2009; Sofroniew & Vinters, 2010]), representing a high potential for formation of virus reservoirs (reviewed in [Borgmann & Ghorpade, 2015; Churchill & Nath, 2013]).”
BackgroundInfluentialFatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“All AAV vectors contained a cytomegalovirus (CMV) promoter-driven reporter gene encoding the enhanced yellow fluorescence protein (EYFP; Grimm et al., 2006).”
BackgroundSelf-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 3×
“Wild-type AAV9 has been shown to cross the BBB after tail vein injection in mice (Cearley & Wolfe, 2006; Foust et al., 2008; Gray et al., 2011), supporting its use for CNS applications.”
BackgroundThe Mystery and Magic of Glia: A Perspective on Their Roles in Health and Disease
Barres, B. A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.013 · Cited by 1,352 · cited 1×
“…include maintenance of the blood–brain barrier (BBB), of glutamate balance, and of ion and water homeostasis, as well as regulation of synapse formation, neural circuit development and brain antioxidant defense (Allaman, B elanger, & Magistretti, 2011; Barres, 2008; Sofroniew & Vinters, 2010).”
BackgroundAstrocyte reactivity and reactive astrogliosis: costs and benefits
Pekny, M., & Pekna, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00041.2013 · Cited by 934
Astrocytes and disease: a neurodevelopmental perspective
Molofsky, A. V., Krenick, R., Ullian, E., Tsai, H.-H., Deneen, B., Richardson, W. D., Barres, B. A., & Rowitch, D. H. (2012) · Genes & Development · doi:10.1101/gad.188326.112 · Cited by 682 · cited 2×
“This supports further exploration of AAV9P1 as a tool to promote the development of novel therapies of various CNS diseases including neurodevelopmental diseases like Alexander Disease or Rett Syndrome (Molofsky et al., 2012), and other diseases involving astrocytes like Huntington’s disease, Parkinson’s disease, Alzh…”
BackgroundHarnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565 · cited 2×
“We targeted the HIV-1 proviral LTR, because it is required for expression of all viral products (Frankel & Young, 1998; Pereira, 2000) and because other studies have demonstrated the feasibility of this approach (Ebina et al., 2013; Hu et al., 2014; Kaminski et al., 2016; Zhu et al., 2015).”
BackgroundResultRNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405186111 · Cited by 527 · cited 3×
“…support the capacity of the CRISPR/Cas9 machinery to inactivate HIV-1 proviruses by disruptive mutation (Ebina, Misawa, Kanemura, & Koyanagi, 2013; Hu et al., 2014; Kaminski, Bella, et al., 2016; Kaminski, Chen, et al., 2016; Wang, Zhao, Berkhout, & Das, 2017; Yin et al., 2017; Zhu et al., 2015).”
BackgroundResultGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 3×
“Wild-type AAV9 has been shown to cross the BBB after tail vein injection in mice (Cearley & Wolfe, 2006; Foust et al., 2008; Gray et al., 2011), supporting its use for CNS applications.”
BackgroundAstrocytes in Neurodegenerative Disease: Table 1.
Phatnani, H., & Maniatis, T. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020628 · Cited by 420 · cited 1×
“…of various CNS diseases including neurodevelopmental diseases like Alexander Disease or Rett Syndrome (Molofsky et al., 2012), and other diseases involving astrocytes like Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and amylotrophic lateral sclerosis (Phatnani & Maniatis, 2015).”
BackgroundAdeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291 · cited 1×
“Furthermore, the natural AAV serotype 9 (AAV9) has been shown to enter the brain in numerous animal studies and has been used in clinical trials for CNS diseases in humans (Foust et al., 2008; Hocquemiller et al., 2016; Zincarelli et al., 2008).”
BackgroundEllis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-74 · Cited by 252 · cited 1×
“Studies in a large number of animal species including mice, dogs, and non-human primates, as well as numerous clinical trials in humans, confirmed their high transduction efficacy and their safety as a gene delivery vector (Ellis et al., 2013; Zincarelli, Soltys, Rengo, & Rabinowitz, 2008).”
Background
Cited by
Capsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
New approaches for brain repair-from rescue to reprogramming
Barker, R. A., Götz, M., & Parmar, M. (2018) · Nature · doi:10.1038/s41586-018-0087-1 · Cited by 214
Uzbas, F., Opperer, F., Sönmezer, C., Shaposhnikov, D., Sass, S., Krendl, C., Angerer, P., Theis, F. J., Mueller, N. S., & Drukker, M. (2019) · Genome Biology · doi:10.1186/s13059-019-1748-6 · Cited by 23
Self-citationProgression and application of CRISPR-Cas genomic editors
Yang, L., Tang, J., Ma, X., Lin, Y., Ma, G., Shan, M., Wang, L., & Yang, Y. (2021) · Methods · doi:10.1016/j.ymeth.2021.03.013 · Cited by 10
Metadata
- Authors
- Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov‐Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., & Brack‐Werner, R.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2017-11-09
- Volume
- 66
- Issue
- 2
- Pages
- 413-427
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2767267170
- Cited by
- 79
- References
- 17
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.